Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer
NCT07565857
·
clinicaltrials.gov ↗
NA
Phase
NOT_YET_RECRUITING
Status
1000
Enrollment
INDUSTRY
Sponsor class
Conditions
Gastric-Esophageal Cancer
Interventions
DEVICE:
Signatera Genome ultra-sensitive ctDNA blood test
Sponsor
Natera, Inc.